New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT05223231

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called LBL-019, given alone or with another immunotherapy, in 26 adults with advanced cancers that no longer responded to standard treatments. The main goal was to check safety and find the right dose. Researchers also looked at whether the drug helped shrink tumors or control the disease. Since participants had late-stage cancers and the study was small, this is not a cure but aims to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350000, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410006, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • The first affiliated hospital with Nanjing medical university

    Nanjing, Jiangsu, 210000, China

  • Union hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China